Versant Ventures | Activity | F4

Team Portfolio Raise Essays

F4/Versant Ventures/Activity

Versant Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company Anokion ceased operations (out of business exit).

Anokion

AnokionVersant Ventures

pitchbook.comDEC 6, 2025

DEC 6, 2025

Investment

Launched Dayra Therapeutics with $70M total funding including $50M from Biogen partnership for oral macrocyclic peptides.

Dayra Therapeutics

Dayra TherapeuticsVersant Ventures

finance.yahoo.comNOV 24, 2025

NOV 24, 2025

Investment

Participated in $65M Series B for Gate Bioscience, advancing oral molecular gate medicines for inflammatory and neurological diseases.

Gate Bioscience

Gate Bioscience Versant Ventures

globenewswire.comNOV 13, 2025

NOV 13, 2025

Exit

Portfolio company SixPeaks Bio acquired by AstraZeneca for up to $300M to advance obesity treatments with muscle preservation.

SixPeaks Bio AG

SixPeaks Bio AG Versant Ventures

startupticker.chOCT 22, 2025

OCT 22, 2025

4 investments· JAN 2025 – SEP 2025Show all

Investment

Co-led $50M Series A for AllRock Bio to advance ROC-101, a first-in-class ROCK inhibitor for pulmonary hypertension.

AllRock Bio

AllRock Bio Versant Ventures

prnewswire.comSEP 16, 2025

SEP 16, 2025

Investment

Co-led $65M Series A for Dualitas Therapeutics to advance bispecific antibodies for immune and inflammatory disease.

Dualitas Therapeutics

Dualitas Therapeutics Versant Ventures

prnewswire.comSEP 16, 2025

SEP 16, 2025

Investment

Led Series A investment in SixPeaks Bio, developing obesity therapeutics with preserved lean muscle mass.

SixPeaks Bio AG

SixPeaks Bio AG Versant Ventures

biopharmadive.comMAY 2025

MAY 2025

Investment

Co-led $65M Series A for Helicore Biopharma, a GIP antagonist developer focused on obesity therapeutics.

Helicore Biopharma

Helicore Biopharma Versant Ventures

globenewswire.comJAN 28, 2025

JAN 28, 2025